Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease

Patrik Fazio, Per Svenningsson, Anton Forsberg, Erik G. Jönsson, Nahid Amini, Ryuji Nakao, Sangram Nag, Christer Halldin, Lars Farde and Andrea Varrone
Journal of Nuclear Medicine May 2015, 56 (5) 714-720; DOI: https://doi.org/10.2967/jnumed.114.152421
Patrik Fazio
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Svenningsson
2Karolinska Institutet, Department of Neurology and Clinical Neuroscience, Centre for Molecular Medicine, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anton Forsberg
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik G. Jönsson
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
3Norment, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nahid Amini
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryuji Nakao
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sangram Nag
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christer Halldin
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Farde
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
4AstraZeneca Translational Science Centre at Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Varrone
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 56 no. 5 714-720
DOI 
https://doi.org/10.2967/jnumed.114.152421
PubMed 
25791993

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication November 28, 2014
  • Accepted for publication February 25, 2015
  • Published online May 1, 2015.

Article Versions

  • previous version (March 19, 2015 - 06:34).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Patrik Fazio1,
  2. Per Svenningsson2,
  3. Anton Forsberg1,
  4. Erik G. Jönsson1,3,
  5. Nahid Amini1,
  6. Ryuji Nakao1,
  7. Sangram Nag1,
  8. Christer Halldin1,
  9. Lars Farde1,4 and
  10. Andrea Varrone1
  1. 1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  2. 2Karolinska Institutet, Department of Neurology and Clinical Neuroscience, Centre for Molecular Medicine, Stockholm, Sweden
  3. 3Norment, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; and
  4. 4AstraZeneca Translational Science Centre at Karolinska Institutet, Stockholm, Sweden
  1. For correspondence or reprints contact: Patrik Fazio, Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, R5:02. SE-17176, Stockholm, Sweden. E-mail: patrik.fazio{at}ki.se
View Full Text

Statistics from Altmetric.com

Cited By...

  • 48 Citations
  • 46 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
    Fatemeh N. Emamzadeh, Andrei Surguchov
    Frontiers in Neuroscience 2018 12
  • Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
    Aurelija Jucaite, Per Svenningsson, Juha O. Rinne, Zsolt Cselényi, Katarina Varnäs, Peter Johnström, Nahid Amini, Anna Kirjavainen, Semi Helin, Margaret Minkwitz, Alan R. Kugler, Joel A. Posener, Samantha Budd, Christer Halldin, Andrea Varrone, Lars Farde
    Brain 2015 138 9
  • Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts
    Usman Saeed, Jordana Compagnone, Richard I. Aviv, Antonio P. Strafella, Sandra E. Black, Anthony E. Lang, Mario Masellis
    Translational Neurodegeneration 2017 6 1
  • EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
    Silvia Morbelli, Giuseppe Esposito, Javier Arbizu, Henryk Barthel, Ronald Boellaard, Nico I. Bohnen, David J Brooks, Jacques Darcourt, John C. Dickson, David Douglas, Alexander Drzezga, Jacob Dubroff, Ozgul Ekmekcioglu, Valentina Garibotto, Peter Herscovitch, Phillip Kuo, Adriaan Lammertsma, Sabina Pappata, Iván Peñuelas, John Seibyl, Franck Semah, Livia Tossici-Bolt, Elsmarieke Van de Giessen, Koen Van Laere, Andrea Varrone, Michele Wanner, George Zubal, Ian Law
    European Journal of Nuclear Medicine and Molecular Imaging 2020 47 8
  • Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease
    Silvia Paola Caminiti, Luca Presotto, Damiano Baroncini, Valentina Garibotto, Rosa Maria Moresco, Luigi Gianolli, Maria Antonietta Volonté, Angelo Antonini, Daniela Perani
    NeuroImage: Clinical 2017 14
  • Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes
    Usman Saeed, Anthony E. Lang, Mario Masellis
    Frontiers in Neurology 2020 11
  • Nigrostriatal dopamine transporter availability in early Parkinson's disease
    Patrik Fazio, Per Svenningsson, Zsolt Cselényi, Christer Halldin, Lars Farde, Andrea Varrone
    Movement Disorders 2018 33 4
  • CDNF Protein Therapy in Parkinson’s Disease
    Henri J. Huttunen, Mart Saarma
    Cell Transplantation 2019 28 4
  • Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison
    Susanna Jakobson Mo, Jan Axelsson, Lars Jonasson, Anne Larsson, Mattias J. Ögren, Margareta Ögren, Andrea Varrone, Linda Eriksson, David Bäckström, Sara af Bjerkén, Jan Linder, Katrine Riklund
    EJNMMI Research 2018 8 1
  • Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review
    Giovanni Palermo, Sara Giannoni, Gabriele Bellini, Gabriele Siciliano, Roberto Ceravolo
    International Journal of Molecular Sciences 2021 22 20

Article usage

Article usage: March 2015 to April 2025

AbstractFullPdf
Mar 2015224051
Apr 2015132043
May 20157362468
Jun 20151721926
Jul 20152241428
Aug 201585613
Sep 201597313
Oct 2015731419
Nov 2015681619
Dec 2015612415
Jan 2016662230
Feb 2016501018
Mar 2016641338
Apr 2016611519
May 2016452330
Jun 2016442620
Jul 2016291321
Aug 201646517
Sep 2016501718
Oct 201627312
Nov 2016431922
Dec 201638812
Jan 20171731725
Feb 2017561720
Mar 2017441222
Apr 20174776
May 2017391218
Jun 201731159
Jul 20172669
Aug 20173663
Sep 2017421115
Oct 2017451310
Nov 201734911
Dec 201742128
Jan 201847512
Feb 201854816
Mar 201844522
Apr 201837923
May 2018221519
Jun 201821516
Jul 20182669
Aug 201823614
Sep 201834914
Oct 20181699
Nov 201826815
Dec 20181118
Jan 2019211026
Feb 201914219
Mar 2019191024
Apr 201922823
May 201928614
Jun 201913710
Jul 201919823
Aug 201912410
Sep 201932915
Oct 201918514
Nov 201917612
Dec 201917610
Jan 20202247
Feb 202015813
Mar 202017610
Apr 20201698
May 202018812
Jun 202027514
Jul 202015410
Aug 20201118
Sep 202034817
Oct 20201819
Nov 202015423
Dec 20205616
Jan 20212613
Feb 2021101825
Mar 202161314
Apr 202141110
May 20218129
Jun 2021121211
Jul 2021141024
Aug 202141010
Sep 202171010
Oct 202161023
Nov 2021161225
Dec 2021161811
Jan 2022132011
Feb 202281517
Mar 202223111
Apr 202215107
May 202211209
Jun 2022101414
Jul 202262812
Aug 202210911
Sep 20223119
Oct 2022443
Nov 2022101820
Dec 20225167
Jan 202357616
Feb 2023111315
Mar 20233368
Apr 20235166
May 202341313
Jun 202315128
Jul 202381910
Aug 202351414
Sep 202381812
Oct 2023102110
Nov 20236329
Dec 2023110116
Jan 2024283721
Feb 2024111514
Mar 202461043
Apr 2024121923
May 202482414
Jun 202461611
Jul 202471911
Aug 202473312
Sep 202453516
Oct 20248138
Nov 2024397
Dec 20247265
Jan 202552218
Feb 2025510511
Mar 2025125431
Apr 2025133535
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 56 (5)
Journal of Nuclear Medicine
Vol. 56, Issue 5
May 1, 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
Patrik Fazio, Per Svenningsson, Anton Forsberg, Erik G. Jönsson, Nahid Amini, Ryuji Nakao, Sangram Nag, Christer Halldin, Lars Farde, Andrea Varrone
Journal of Nuclear Medicine May 2015, 56 (5) 714-720; DOI: 10.2967/jnumed.114.152421

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
Patrik Fazio, Per Svenningsson, Anton Forsberg, Erik G. Jönsson, Nahid Amini, Ryuji Nakao, Sangram Nag, Christer Halldin, Lars Farde, Andrea Varrone
Journal of Nuclear Medicine May 2015, 56 (5) 714-720; DOI: 10.2967/jnumed.114.152421
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders
  • Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects
  • Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
  • Google Scholar

More in this TOC Section

  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
  • Prognostic Role of 68Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy
Show more Clinical Investigations

Similar Articles

Keywords

  • dopamine transporter
  • Parkinson disease
  • Substantia Nigra
  • PET
SNMMI

© 2025 SNMMI

Powered by HighWire